Phase I Study to Determine the Effect of a High Fat Meal on the Pharmacokinetics of BMS-540215, the Active Metabolite of Brivanib Alaninate in Subjects With Advanced or Metastatic Solid Tumors.
Latest Information Update: 26 Jun 2013
At a glance
- Drugs Brivanib alaninate (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 07 Feb 2013 Planned end date changed from 1 Jun 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 14 Dec 2011 Planned end date changed from 1 Nov 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 17 May 2011 Planned end date changed from 1 Oct 2010 to 1 Nov 2011 as reported by ClinicalTrials.gov.